Quarterly report · Q2
3353.TEDINET S100S0UE
Period2023-03-01 → 2023-08-31
Filed2023-10-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥17.5bn | 2023-03-01 → 2023-08-31 | Cons. | Net sales |
| Revenue | ¥33.9bn | 2022-03-01 → 2023-02-28 | Cons. | Net sales (5-year summary) |
| Revenue | ¥17.0bn | 2022-03-01 → 2022-08-31 | Cons. | Net sales |
| Operating income | ¥603m | 2023-03-01 → 2023-08-31 | Cons. | Operating income |
| Operating income | ¥466m | 2022-03-01 → 2022-08-31 | Cons. | Operating income |
| Ordinary income | ¥697m | 2023-03-01 → 2023-08-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2022-03-01 → 2023-02-28 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥598m | 2022-03-01 → 2022-08-31 | Cons. | Ordinary income |
| Profit before tax | ¥776m | 2023-03-01 → 2023-08-31 | Cons. | Income before income taxes |
| Profit before tax | ¥624m | 2022-03-01 → 2022-08-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥444m | 2023-03-01 → 2023-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥760m | 2022-03-01 → 2023-02-28 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥374m | 2022-03-01 → 2022-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥469m | 2023-03-01 → 2023-08-31 | Cons. | Profit loss |
| Net income | ¥386m | 2022-03-01 → 2022-08-31 | Cons. | Profit loss |
| Total assets | ¥28.5bn | at 2023-08-31 | Cons. | Assets |
| Total assets | ¥27.5bn | at 2023-02-28 | Cons. | Assets |
| Total assets | ¥28.3bn | at 2022-08-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥15.4bn | at 2023-08-31 | Cons. | Liabilities |
| Total liabilities | ¥14.9bn | at 2023-02-28 | Cons. | Liabilities |
| Net assets / equity | ¥13.1bn | at 2023-08-31 | Cons. | Net assets |
| Net assets / equity | ¥12.6bn | at 2023-02-28 | Cons. | Net assets |
| Net assets / equity | ¥12.2bn | at 2022-08-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥6.7bn | at 2023-08-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥6.4bn | at 2023-02-28 | Cons. | Cash and deposits |
| Cash & equivalents | ¥6.5bn | at 2023-08-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.3bn | at 2023-02-28 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.8bn | at 2022-08-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.8bn | at 2022-02-28d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥848m | 2023-03-01 → 2023-08-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.3bn | 2022-03-01 → 2023-02-28 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥496m | 2022-03-01 → 2022-08-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥338m | 2023-03-01 → 2023-08-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥478m | 2022-03-01 → 2023-02-28 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥291m | 2022-03-01 → 2022-08-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥217m | 2023-03-01 → 2023-08-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥2.4bn | 2022-03-01 → 2023-02-28 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.2bn | 2022-03-01 → 2022-08-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥118.26 | 2023-03-01 → 2023-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥61.84 | 2023-06-01 → 2023-08-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥202.2 | 2022-03-01 → 2023-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥99.65 | 2022-03-01 → 2022-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥44.26 | 2022-06-01 → 2022-08-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 43.9% | at 2023-08-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.8% | at 2023-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.2% | at 2022-08-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-03-01 → 2023-08-31 | −¥472m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-03-01 → 2023-08-31 | −¥472m |
| Reconciling Itemsreconciling | segment profit | 2023-03-01 → 2023-08-31 | −¥387m |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2023-03-01 → 2023-08-31 | ¥11.9bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2023-03-01 → 2023-08-31 | ¥11.9bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2023-03-01 → 2023-08-31 | ¥780m |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue | 2023-03-01 → 2023-08-31 | ¥3.9bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue external | 2023-03-01 → 2023-08-31 | ¥3.9bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue intersegment | 2023-03-01 → 2023-08-31 | ¥300,000 |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | segment profit | 2023-03-01 → 2023-08-31 | ¥111m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue | 2023-03-01 → 2023-08-31 | ¥2.1bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2023-03-01 → 2023-08-31 | ¥1.6bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2023-03-01 → 2023-08-31 | ¥470m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2023-03-01 → 2023-08-31 | ¥34m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue | 2023-03-01 → 2023-08-31 | ¥93m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue external | 2023-03-01 → 2023-08-31 | ¥91m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue intersegment | 2023-03-01 → 2023-08-31 | ¥2m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | segment profit | 2023-03-01 → 2023-08-31 | ¥66m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-03-01 → 2023-08-31 | ¥17.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-03-01 → 2023-08-31 | ¥17.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-03-01 → 2023-08-31 | ¥472m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-03-01 → 2023-08-31 | ¥990m |
| Reconciling Itemsreconciling | revenue | 2022-03-01 → 2022-08-31 | −¥497m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-03-01 → 2022-08-31 | −¥497m |
| Reconciling Itemsreconciling | segment profit | 2022-03-01 → 2022-08-31 | −¥385m |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2022-03-01 → 2022-08-31 | ¥11.6bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2022-03-01 → 2022-08-31 | ¥11.6bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2022-03-01 → 2022-08-31 | ¥736m |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue | 2022-03-01 → 2022-08-31 | ¥3.9bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue external | 2022-03-01 → 2022-08-31 | ¥3.9bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue intersegment | 2022-03-01 → 2022-08-31 | ¥300,000 |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | segment profit | 2022-03-01 → 2022-08-31 | ¥35m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue | 2022-03-01 → 2022-08-31 | ¥1.9bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2022-03-01 → 2022-08-31 | ¥1.4bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2022-03-01 → 2022-08-31 | ¥495m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2022-03-01 → 2022-08-31 | ¥20m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue | 2022-03-01 → 2022-08-31 | ¥95m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue external | 2022-03-01 → 2022-08-31 | ¥94m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue intersegment | 2022-03-01 → 2022-08-31 | ¥876,000 |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | segment profit | 2022-03-01 → 2022-08-31 | ¥61m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-03-01 → 2022-08-31 | ¥17.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-03-01 → 2022-08-31 | ¥17.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-03-01 → 2022-08-31 | ¥497m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-03-01 → 2022-08-31 | ¥851m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 499
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)有限責任監査法人ト ー マ ツ | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)神 野 敦 生 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)牧 野 秀 俊 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1YTDDuration | 16978990000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 17450480000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 33897598000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | 598347000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | 696659000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 1227454000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | 374340000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | 444369000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 759598000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | 352248000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | 555192000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 827629000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 12207602000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 13090270000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 12607842000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 28308163000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 28480670000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 27505776000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | 99.65 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | 118.26 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 202.20 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | － | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | － | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.412 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.439 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.438 | |
| Net cash provided by used in operating activities (5-year summary) | Prior1YTDDuration | 496298000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | CurrentYTDDuration | 847550000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | 1307596000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YTDDuration | -291276000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYTDDuration | -338155000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | -477521000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YTDDuration | -1163874000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYTDDuration | -217387000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | -2366769000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1QuarterInstant | 6830946000 | JPY |
| Cash and cash equivalents (5-year summary) | CurrentQuarterInstant | 6545111000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant | 6253102000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1QuarterDuration | 44.26 | |
| Basic earnings loss per share (5-year summary) | CurrentQuarterDuration | 61.84 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 4070000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 4070000 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 4070000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 4070000 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |